Literature DB >> 19088479

Serum and tissue LDH levels in patients with breast/gynaecological cancer and benign diseases.

Michael I Koukourakis1, Emmanuel Kontomanolis, Alexandra Giatromanolaki, Efthimios Sivridis, Vassilios Liberis.   

Abstract

BACKGROUND: Lactate dehydrogenase A (LDHA) is involved in anaerobic glycolysis. In cancer patients, serum total lactate dehydrogenase (LDH) levels are often increased, and the gene for one of its isoenzymes, LDHA, is up-regulated. These features have been linked to poor prognosis in several studies.
METHODS: We investigated comparatively the total serum LDH activity and tissue isoenzyme LDH5 and hypoxia-inducible factor 1alpha (HIF1alpha) levels in patients with breast (n = 18) and gynaecological (n = 23) malignancies and benign diseases (n =54).
RESULTS: The serum LDH levels were significantly higher in patients with endometrial adenocarcinoma (349 +/- 100 IU/l) and ovarian cystadenocarcinomas (383 +/- 116 IU/l) compared to healthy controls (256 +/- 68 IU/l) (p values 0.01 and 0.006, respectively). This difference did not reach significance in patients with breast cancer (328 +/- 169 IU/l; p = 0.17)). Uterine leiomyoma patients showed intermediate LDH levels (310 +/- 81 IU/l), while patients with breast fibroadenomas and ovarian cystadenomas had LDH serum levels close to carcinomas (308 +/- 60 and 348 +/- 135 IU/l, respectively). LDH5 isoenzyme was strongly expressed in cancer cells, exhibiting a mixed cytoplasmic/nuclear subcellular pattern. Interestingly, a high LDH5 content in tissue sections was not invariably accompanied by high LDH serum levels. High HIF1alpha tissue expression was linked to high tissue LDH5 expression.
CONCLUSION: Serum and tissue LDH is up-regulated in gynaecologic and breast malignancies and in a subset of benign conditions such as fibro- and cystadenomas. The release of LDH, however, in the bloodstream is partly related to the LDHA gene up-regulation. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19088479     DOI: 10.1159/000183250

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  37 in total

1.  Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer.

Authors:  Lynn M Amon; Sharon J Pitteri; Christopher I Li; Martin McIntosh; Jon J Ladd; Mary Disis; Peggy Porter; Chee Hong Wong; Qing Zhang; Paul Lampe; Ross L Prentice; Samir M Hanash
Journal:  Cancer Res       Date:  2012-02-24       Impact factor: 12.701

2.  FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.

Authors:  Jiujie Cui; Min Shi; Dacheng Xie; Daoyan Wei; Zhiliang Jia; Shaojiang Zheng; Yong Gao; Suyun Huang; Keping Xie
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

3.  Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism.

Authors:  Gloria Bonuccelli; Aristotelis Tsirigos; Diana Whitaker-Menezes; Stephanos Pavlides; Richard G Pestell; Barbara Chiavarina; Philippe G Frank; Neal Flomenberg; Anthony Howell; Ubaldo E Martinez-Outschoorn; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-09-21       Impact factor: 4.534

4.  LDH-A influences hypoxia-inducible factor 1α (HIF1 α) and is critical for growth of HT29 colon carcinoma cells in vivo.

Authors:  Stefan Langhammer; Maher Najjar; Holger Hess-Stumpp; Karl-Heinz Thierauch
Journal:  Target Oncol       Date:  2011-06-10       Impact factor: 4.493

5.  BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

Authors:  Kevin B Kim; Jeffrey A Sosman; John P Fruehauf; Gerald P Linette; Svetomir N Markovic; David F McDermott; Jeffrey S Weber; Hoa Nguyen; Peter Cheverton; Daniel Chen; Amy C Peterson; William E Carson; Steven J O'Day
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

Review 6.  LDH-C4: a target with therapeutic potential for cancer and contraception.

Authors:  G S Gupta
Journal:  Mol Cell Biochem       Date:  2012-08-15       Impact factor: 3.396

7.  The regulation of skeletal muscle fiber-type composition by betaine is associated with NFATc1/MyoD.

Authors:  Jingjing Du; Linyuan Shen; Peiwen Zhang; Zhendong Tan; Xiao Cheng; Jia Luo; Xue Zhao; Qiong Yang; Hao Gu; An'an Jiang; Jideng Ma; Qianzi Tang; Long Jin; Surong Shuai; Mingzhou Li; Yanzhi Jiang; Guoqing Tang; Lin Bai; Xuewei Li; Jinyong Wang; Shunhua Zhang; Li Zhu
Journal:  J Mol Med (Berl)       Date:  2018-06-06       Impact factor: 4.599

8.  Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer.

Authors:  Di Zhao; Shao-Wu Zou; Ying Liu; Xin Zhou; Yan Mo; Ping Wang; Yan-Hui Xu; Bo Dong; Yue Xiong; Qun-Ying Lei; Kun-Liang Guan
Journal:  Cancer Cell       Date:  2013-03-21       Impact factor: 31.743

9.  Preliminary Study on Serum Lactate Dehydrogenase (LDH)-Prognostic Biomarker in Carcinoma Breast.

Authors:  Aditi Agrawal; Mahendra Bhauraoji Gandhe; Dilip Gupta; M V R Reddy
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 10.  Biomarkers in uterine leiomyoma.

Authors:  Gary Levy; Micah J Hill; Torie C Plowden; William H Catherino; Alicia Y Armstrong
Journal:  Fertil Steril       Date:  2012-11-29       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.